Abstract
Multiple sclerosis (MS) is characterized by demyelinating lesions disseminated throughout the central nervous system, and a progressive axonal degeneration. In this review we propose that an impaired cAMP signaling in white mater astrocytes, caused by a deficiency of β2-adrenergic receptors, may play a role in the pathogenesis of the disease. Reduced astrocytic cAMP signaling may, in a proinflammatory environment, facilitate astrocytes to become facultative antigen presenting cells, stimulating the development of inflammatory demyelinating lesions. It may reduce astrocytic glycogenolysis, which supplies energy and N-acetylaspartate (NAA) to axons and oligodendrocytes, reduce trophic and neuroprotective support to oligodendrocytes and neurons, and enhance astrogliosis.
Keywords: Multiple sclerosis, astrocytes, β2-adrenergic receptors, cAMP, demyelination, axonal degeneration, astrocyte signaling, immune hypothesis, impaired energy metabolism, plasma cells
Current Signal Transduction Therapy
Title: Astrocyte Signaling and Multiple Sclerosis
Volume: 7 Issue: 1
Author(s): Miguel D'haeseleer, Melissa Cambron and Jacques De Keyser
Affiliation:
Keywords: Multiple sclerosis, astrocytes, β2-adrenergic receptors, cAMP, demyelination, axonal degeneration, astrocyte signaling, immune hypothesis, impaired energy metabolism, plasma cells
Abstract: Multiple sclerosis (MS) is characterized by demyelinating lesions disseminated throughout the central nervous system, and a progressive axonal degeneration. In this review we propose that an impaired cAMP signaling in white mater astrocytes, caused by a deficiency of β2-adrenergic receptors, may play a role in the pathogenesis of the disease. Reduced astrocytic cAMP signaling may, in a proinflammatory environment, facilitate astrocytes to become facultative antigen presenting cells, stimulating the development of inflammatory demyelinating lesions. It may reduce astrocytic glycogenolysis, which supplies energy and N-acetylaspartate (NAA) to axons and oligodendrocytes, reduce trophic and neuroprotective support to oligodendrocytes and neurons, and enhance astrogliosis.
Export Options
About this article
Cite this article as:
D'haeseleer Miguel, Cambron Melissa and De Keyser Jacques, Astrocyte Signaling and Multiple Sclerosis, Current Signal Transduction Therapy 2012; 7 (1) . https://dx.doi.org/10.2174/157436212799278133
DOI https://dx.doi.org/10.2174/157436212799278133 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry miR-629-3p Level Significantly Predicts Prognosis in Glioblastoma Patients Treated with Temozolomide Chemotherapy
Current Signal Transduction Therapy Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology Using Nutrigenomics to Evaluate Apoptosis as a Preemptive Target in Cancer Prevention
Current Cancer Drug Targets Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers
Recent Patents on Anti-Cancer Drug Discovery Nanostructures for Bypassing Blood Brain Barrier
Current Bioactive Compounds Angiogenesis New Targets for the Development of Anticancer Chemotherapies
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Pharmacogenomics and Personalized Medicine PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Zinc, Metallothioneins and Longevity: Interrelationships with Niacin and Selenium
Current Pharmaceutical Design Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale
Current Pharmaceutical Design Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Investigation of Image Processing Techniques in MRI Based Medical Image Analysis Methods and Validation Metrics for Brain Tumor
Current Medical Imaging Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design Fetal Mesenchymal Stem Cells in Cancer Therapy
Current Stem Cell Research & Therapy Oxidative Stress and NAD+ in Ischemic Brain Injury: Current Advances and Future Perspectives
Current Medicinal Chemistry microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design